These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. Abdel-Fatah TM; Middleton FK; Arora A; Agarwal D; Chen T; Moseley PM; Perry C; Doherty R; Chan S; Green AR; Rakha E; Ball G; Ellis IO; Curtin NJ; Madhusudan S Mol Oncol; 2015 Mar; 9(3):569-85. PubMed ID: 25468710 [TBL] [Abstract][Full Text] [Related]
3. RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Yang X; Pan Y; Qiu Z; Du Z; Zhang Y; Fa P; Gorityala S; Ma S; Li S; Chen C; Wang H; Xu Y; Yan C; Ruth K; Ma Z; Zhang J Clin Cancer Res; 2018 Apr; 24(7):1629-1643. PubMed ID: 29326282 [No Abstract] [Full Text] [Related]
4. Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response. Al-Kaabi MM; Alshareeda AT; Jerjees DA; Muftah AA; Green AR; Alsubhi NH; Nolan CC; Chan S; Cornford E; Madhusudan S; Ellis IO; Rakha EA Br J Cancer; 2015 Mar; 112(5):901-11. PubMed ID: 25688741 [TBL] [Abstract][Full Text] [Related]
5. Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein. Alshareeda AT; Negm OH; Aleskandarany MA; Green AR; Nolan C; TigHhe PJ; Madhusudan S; Ellis IO; Rakha EA Breast Cancer Res Treat; 2016 Aug; 159(1):41-53. PubMed ID: 27464795 [TBL] [Abstract][Full Text] [Related]
6. Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. Agboola AJ; Musa AA; Wanangwa N; Abdel-Fatah T; Nolan CC; Ayoade BA; Oyebadejo TY; Banjo AA; Deji-Agboola AM; Rakha EA; Green AR; Ellis IO Breast Cancer Res Treat; 2012 Sep; 135(2):555-69. PubMed ID: 22842985 [TBL] [Abstract][Full Text] [Related]
7. Thymoquinone triggers inactivation of the stress response pathway sensor CHEK1 and contributes to apoptosis in colorectal cancer cells. Gali-Muhtasib H; Kuester D; Mawrin C; Bajbouj K; Diestel A; Ocker M; Habold C; Foltzer-Jourdainne C; Schoenfeld P; Peters B; Diab-Assaf M; Pommrich U; Itani W; Lippert H; Roessner A; Schneider-Stock R Cancer Res; 2008 Jul; 68(14):5609-18. PubMed ID: 18632613 [TBL] [Abstract][Full Text] [Related]
8. Tumour cell membrane laminin expression is associated with basal-like phenotype and poor survival in Nigerian breast cancer. Agboola AO; Ebili HO; Iyawe VO; Banjo AA; Salami BS; Rakha EA; Nolan C; Ellis IO; Green AR Malays J Pathol; 2016 Aug; 38(2):83-92. PubMed ID: 27568664 [TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications. Agboola AO; Ebili HO; Iyawe VO; Banjo AA; Salami BA; Rakha EA; Nolan CC; Ellis IO; Green AR Pathol Res Pract; 2017 Jan; 213(1):27-33. PubMed ID: 27914769 [TBL] [Abstract][Full Text] [Related]
10. Histological Features and Tissue Microarray Taxonomy of Nigerian Breast Cancer Reveal Predominance of the High-Grade Triple-Negative Phenotype. Titloye NA; Foster A; Omoniyi-Esan GO; Komolafe AO; Daramola AO; Adeoye OA; Adisa AO; Manoharan A; Pathak D; D'Cruz MN; Alizadeh Y; Lewis PD; Shaaban AM Pathobiology; 2016; 83(1):24-32. PubMed ID: 26730581 [TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers. De Brot M; Rocha RM; Soares FA; Gobbi H Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210 [TBL] [Abstract][Full Text] [Related]
12. PIASγ expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women. Agboola A; Musa A; Banjo A; Ayoade B; Deji-Agboola M; Nolan C; Rakha E; Ellis I; Green A J Clin Pathol; 2014 Apr; 67(4):301-6. PubMed ID: 24170211 [TBL] [Abstract][Full Text] [Related]
13. Tan Z; Chen M; Wang Y; Peng F; Zhu X; Li X; Zhang L; Li Y; Liu Y Biomark Med; 2022 Feb; 16(2):83-100. PubMed ID: 34882011 [TBL] [Abstract][Full Text] [Related]
14. KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer. Alshareeda AT; Negm OH; Green AR; Nolan CC; Tighe P; Albarakati N; Sultana R; Madhusudan S; Ellis IO; Rakha EA Br J Cancer; 2015 Jun; 112(12):1929-37. PubMed ID: 25989275 [TBL] [Abstract][Full Text] [Related]
15. High nuclear MSK1 is associated with longer survival in breast cancer patients. Pu X; Storr SJ; Ahmad NS; Rakha EA; Green AR; Ellis IO; Martin SG J Cancer Res Clin Oncol; 2018 Mar; 144(3):509-517. PubMed ID: 29327245 [TBL] [Abstract][Full Text] [Related]
17. Triple-negative breast cancer: current state of the art. Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S Tumori; 2010; 96(6):875-88. PubMed ID: 21388048 [TBL] [Abstract][Full Text] [Related]
18. Molecular profiling of breast cancer in Nigerian women identifies an altered p53 pathway as a major mechanism underlying its poor prognosis compared with British counterpart. Agboola AO; Banjo AA; Anunobi CC; Ayoade BA; Deji-Agboola AM; Musa AA; Abdel-Fatah T; Nolan CC; Rakha EA; Ellis IO; Green AR Malays J Pathol; 2014 Apr; 36(1):3-17. PubMed ID: 24763230 [TBL] [Abstract][Full Text] [Related]
19. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype. Voduc D; Nielsen TO; Cheang MC; Foulkes WD Hum Pathol; 2008 Oct; 39(10):1431-7. PubMed ID: 18620730 [TBL] [Abstract][Full Text] [Related]
20. Expression of embryonal stem cell transcription factors in breast cancer: Oct4 as an indicator for poor clinical outcome and tamoxifen resistance. Gwak JM; Kim M; Kim HJ; Jang MH; Park SY Oncotarget; 2017 May; 8(22):36305-36318. PubMed ID: 28422735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]